argenx SE (EBR:ARGX)

Market Cap	53.48B +58.7%
Revenue (ttm)	4.65B +70.3%
Net Income	1.50B +33.9%
EPS	22.95 +39.8%
Shares Out	62.54M
PE Ratio	37.27
Forward PE	30.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	158,662
Open	794.20
Previous Close	730.20
Day's Range	784.40 - 863.00
52-Week Range	556.20 - 863.00
Beta	-0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 23, 2026

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,863
• Stock Exchange: Euronext Brussels
• Ticker Symbol: ARGX

Financial Performance

In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 17, 2026

Data Sources Report a data error